Form 4 for MGX Metagenomi Therapeutics, Inc.
Accepted 2026-03-09 00:00:00 ET · period of report 2026-03-05 · accession 0001193125-26-098824 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | 2026-03-05 | MGX | Wapnick Pamela | CFO | S - Sale | $1.60 | -1,581 | 187.4K | -0.8% | -$2,530 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-05 | S | D | 1,581 | $1.60 | 187,375 | D | — | — |